Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
- 1 October 2002
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 113 (5) , 400-408
- https://doi.org/10.1016/s0002-9343(02)01243-3
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Long-term morbidity, mortality, and economics of rheumatoid arthritisArthritis & Rheumatism, 2001
- Medical therapy for rheumatoid arthritis—value for money?Rheumatology, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 yearsScandinavian Journal of Rheumatology, 1999
- Gains in Life Expectancy from Medical Interventions — Standardizing Data on OutcomesNew England Journal of Medicine, 1998
- Long-Term Outcomes in Rheumatoid ArthritisRheumatology, 1995
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Locomotion status and costs in destructive rheumatoid arthritisActa Orthopaedica, 1992
- The costs of rheumatoid arthritis. a patient‐oriented study of chronic disease costsArthritis & Rheumatism, 1978